ImetelChat

I thought it might be fun to compile a list of what might go before the FDA at the end of PII meeting presumptively scheduled for March 2020. I invite board members to add or subtract and to help rank order in terms of importance: 1. The MF study that demonstrates significant MOS improvement. That d...

Hunting, you are right about that. The great unknown and Scarlett’s hidden card up his sleeve is whether “disease modification” extends to altering progression to AML. I have submitted this question to annual meetings for the past few years but it has never been adequately addressed. In theory, this...

Well, here is how Blood Advances defines “Stimulus Report” : ”To complement the clinical case reports, we also recognize that there can be more basic scientific insights that also can provide novel information or mechanisms in a short format that we have termed Stimulus Reports. “

Hi Hunting, the issue for ET is that primary treatment is essentially aspirin so there is no market despite impressive anticlonal data. This study emphasizes the selective nature of Imet (a very good attribute) across myleoproliferative diseases, in this case, ET, complementing the previously presen...

So why are we seeing old ET data repackaged and published now? The article I posted is a rehash of 2011 ASH abstract, I don't see anything really new, does anyone else? Dr. Boerlacher has basically been MIA and I have not seen her as an integral part of the MF or MDS studies. This is a glaring absen...

So why are we seeing old ET data repackaged and published now? The article I posted is a rehash of 2011 ASH abstract, I don't see anything really new, does anyone else? Dr. Boerlacher has basically been MIA and I have not seen her as an integral part of the MF or MDS studies. This is a glaring absen...

Seems to be a rehash of old data from 2011 ASH abstract bp

Hi Ryan, the abstract makes mention of the Part I results. If this were an oral presentation the think an update of the Part I data would be appropriate and probably part of the presentation. The poster however will probably just reflect the abstract as presented (but I would love to see more data t...

Ryan, thanks for posting. Good point. Interesting that the primary presenter is European and the big news clinical news seems to find its way to EHA over ASH. bp

First off, thanks to recent posters, hunt and commsman, for their contributions and thoughts. I wanted to mention the "other two" ASH abstracts related to Geron but not acknowledged in the recent PR. You can read them here (in addition to the two that Geron has referenced): https://ash.confex.com/as...

STA, I don't think a new PIII could possibly start out of the gate until further lab studies, dosing studies, human safety studies etc were done. While synergism has its obvious benefits, the potential for synergistic toxicities also need to be evaluated. I think there is much work required before a...

To Ryan's point about AML, when the venetoclax/imet AML study was presented, I essentially went all in (not my smartest investment move), when it was stated that "cures" were effected in a number of mice. We all know that this did not translate into a clinical study, at least as yet, for opaque reas...

Hi Ryan, thank you for your thoughts as usual. Yes it is clear the focus is on single agent use in the clinic now. Perhaps Geron felt it had enough to go to the FDA in Q1 with out providing additional RWD in the public domaine and didn't want to expend energy in this direction. Same for updating the...

J Lennon actually said, "you may say I'm a dreamer, but I'm not the only one." He would have plenty of company on this board. There was no reason I can think of not to update the durability data for TI to further shore up further respect for drug effect, unless there is not. Usually silence is not n...

Ryan, thanks for your post. I see this a little differently. 1. There is no mention of AML probably because the program is probably dead in the water and Scarlett always skirts this issue (its oh so complicated, etc). 2. There are only two(or three counting the one Geron did not mention in the compa...

STA, since those positions remain posted as of today, I think the ever parsimonious Scarlett will deal with this during whatever PR accompanies the Nov 6th "earnings" report and discussion of submissions to ASH. bp

musketeer, yes. That way they have something to talk about ("within the four corners of the abstract(s)). This will help to offset the terrible continuing hemorrhage (and dilution) of $$ as they run to the finish line (FDA meeting Q1). bp